This pilot study evaluates the feasibility, acceptability, usability, and engagement of a smartphone-delivered mindfulness intervention for caregivers of hematopoietic stem cell transplant (HCT) patients. Thirty caregivers will use the app for six weeks beginning the week prior to the patient's transplant. Participants will complete baseline and end-of-treatment surveys and a brief qualitative interview.

开始日期2026-08-01

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT07265739

/ Not yet recruiting临床2期IIT

A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer

The purpose of this Phase II study is to measure the effects of a combination of study drugs, losartan and paclitaxel, on platinum resistant ovarian cancer.

开始日期2026-08-01

申办/合作机构

The Massachusetts General Hospital

[+1]

NCT07539649

/ Not yet recruitingN/A

LiveWell mBC: Pilot Test of an Adapted Dialectical Behavioral Therapy Skills Training Program in Groups of Women Living With Metastatic Breast Cancer

In this pilot randomized controlled trial, women with metastatic breast cancer and at least mild distress (N=48) will be randomized to receive LiveWell mBC, a group-based adapted Dialectical Behavioral Therapy (DBT) Skills Training protocol, or Usual Care. The investigators will evaluate feasibility, acceptability, and preliminary efficacy of LiveWell to reduce distress (primary outcome) and improve psychological well-being, symptom burden, and quality of life (secondary outcomes).

开始日期2026-05-01

申办/合作机构

The Medical University of South Carolina

[+1]

100 项与 American Cancer Society, Inc. 相关的临床结果

登录后查看更多信息

0 项与 American Cancer Society, Inc. 相关的专利（医药）

登录后查看更多信息

793

项与 American Cancer Society, Inc. 相关的文献（医药）

2026-01-01·INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Developing an assessment tool to measure health equity considerations of guideline development handbooks

Article

作者: Ochodo, Eleanor ; Manassaram-Baptiste, Deana ; González Ramos, Ana ; Richards, Adam ; Sagam, Caleb Kimutai ; Turner, Tari ; Chitale, Ramaa ; Kowalsky, Rachel ; McMillan Boyles, Christina ; Williams, Precious ; Goodrick, Stephanie ; Smith, Emily

Abstract:

Objectives:

Guideline development handbooks outline the methodology that authoring organizations use to create public health and clinical practice guidelines (CPGs). We created an Equity Assessment Tool (EquAT) for guideline development handbooks to identify areas of improvement and foster conversations.

Methods:

Sequential phases lead to tool development and face/content validation in this mixed-methods study. In phase 1, we reviewed the literature to generate a list of “essential elements” or tasks that are part of guideline development methodology, mapped “essential elements” with relevant equity concepts, and drafted our tool for use in reviewing guideline development handbooks. In phase 2, we surveyed experts for feedback on “essential elements” and explicit language for assessing equity within the tool and refined items. We piloted and finalized the tool based on feedback.

Results:

We identified 18 essential elements within five domains of guideline development and created a draft EquAT. Twenty of 25 invited experts responded to the online survey for feedback on the tool. Most experts provided limited feedback, and the most common suggestion was adding clarifying language to the existing tool criteria for assessing equity. Ten experts participated in pilot testing the revised tool. We found a diversity of scores, and potential reasons might be due to the complexity of the tool, differences in equity frameworks, and a variety of expertise. We incorporated their feedback and finalized the tool.

Conclusions:

We developed and validated the EquAT, a tool to foster discussion among assessors about the extent of health equity considerations in guideline development handbooks.

2025-12-01·ENVIRONMENTAL RESEARCH

Tracking changes in walkability over time: How our neighborhoods are developing and what it means for health surveillance

Article

作者: Wali, Behram ; Frank, Lawrence D ; Rees-Punia, Erika ; Patel, Alpa

An increasing body of evidence highlights the health-supportive role walkable environments can play by increasing active and reducing sedentary travel, thus lowering chronic disease risks. With increasing urbanization, it is important to assess how built environment characteristics are changing over time. In this context, understanding the extent of geographic and social disparities in the distribution of changes in walkability is also warranted. This study presents a nationwide assessment of how physical environment characteristics known to impact health and welfare are changing over time in the U.S. We integrate longitudinal data for over 164,000 participants in the American Cancer Society's prospective Cancer Prevention Study (CPS-3) cohort with objectively assessed built environment data at two time points (2013 and 2020). Descriptive and longitudinal change detection modeling of a geographically and ethnically diverse national sample of over 109,000 non-movers revealed some improvements in urban compactness, street connectivity, transit accessibility, urban diversity, and overall walkability levels. Changes in walkability across U.S. regions and the urban-rural continuum exhibited geographic disparities. Participants in rural areas and small towns experienced a modest reduction in walkability, whereas the reverse was observed for those in urban areas. Walkability increased over time for all age and racial groups but exhibited considerable variations. The increase in walkability over time was greatest for Hispanics and Blacks compared to non-Hispanic Whites. Results provide background trends and can inform walkability interventions to reduce geographical inequities for the most underserved. Implications of our work for future research are discussed.

2025-08-05·ENVIRONMENTAL SCIENCE & TECHNOLOGY

The Associations of Air Pollution Mixture Exposure with Plasma Proteins in an Elderly U.S. Panel

Article

作者: Wang, Ying ; Tan, Youran ; Deubler, Emily ; Tang, Ziyin ; Johansson, Mattias ; Sarnat, Jeremy A. ; Kesarwala, Aparna H. ; Turner, Michelle C. ; Diver, W.Ryan ; Everson, Todd M. ; Marsit, Carmen J. ; Eick, Stephanie M. ; Liang, Donghai ; Robbins, Hilary A.

The impact of air pollution exposure on circulating proteins remains underexplored, particularly in vulnerable elderly populations. This study investigated the individual and joint effects of air pollutants on circulating proteins in 208 elderly participants from the Cancer Prevention Study-II Nutrition Cohort. Prediagnostic plasma samples were collected (1998-2001), and 484 proteins were measured using the Olink platform. Annual average exposures to six air pollutants in the calendar year of blood draw were estimated. We used linear regression for individual pollutants and quantile g-computation for mixture effects, adjusting for confounders, considering multiple comparison correction, and testing interactions with smoking status. Pathway enrichment and protein-protein interaction analyses were conducted for the associated proteins. We identified 167 distinct proteins associated with individual pollutants or mixtures (p < 0.05), including 15 meeting a false discovery rate <0.2. IL32, ADAM15, and IL8 demonstrated consistent negative associations with ≥4 exposure metrics. Twenty proteins were associated with both mixtures and individual air pollutants with consistent effect directions. These proteins were enriched in pathways linked to immunity and signaling. Stratified analyses revealed differing associations with 99 proteins between current and former smokers. The findings offer valuable insight into the chronic biological response in plasma protein levels to air pollution exposure.

309

项与 American Cancer Society, Inc. 相关的新闻（医药）

2026-05-07

·腾讯网

CellCentric获得2.2亿美元D轮融资

CellCentric是一家英国抗癌药物研发商，其候选药物CCS1477，是一种可口服吸收的组蛋白乙酰转移酶p300和CBP的抑制剂，可以识别这两种蛋白的保守布罗莫结构域，适用于前列腺癌的治疗。近日，CellCentric宣布完成了2.2亿美元的超额认购D轮融资。此次融资由Venrock Healthcare Capital Partners领投，Fidelity、Sofinova Partners和HBM Healthcare以及现有投资者RA Capital Management、Forbion、Pfizer、Avego BioScience Capital和美国癌症协会BrightEdge的参与。

2026-05-07

·Medaverse

2.2亿美元D轮融资，开发口服小分子p300/CBP抑制剂

5月6日，英国剑桥和波士顿，CellCentric是一家临床阶段的生物技术公司，正在开发inobrodib作为治疗多发性骨髓瘤的同类首创口服p300/CBP抑制剂，宣布完成了2.2亿美元的超额认购D轮融资。此次融资由Venrock Healthcare Capital Partners领投，Fidelity、Sofinova Partners和HBM Healthcare以及现有投资者RA Capital Management、Forbion、Pfizer、Avego BioScience Capital和美国癌症协会BrightEdge的参与。2025年5月，CellCentric宣布完成1.2亿美元的C轮融资，RA Capital Management和新投资者Forbion共同领投。（1.2亿美元C轮融资，开发口服小分子p300/CBP抑制剂）2024年，CellCentric获得RA Capital的3500万美元初始投资以及辉瑞的2500万美元战略投资。该公司由剑桥大学的开创性发育生物学家Azim Surani教授从剑桥大学分拆出来，他希望进一步探索染色质相关细胞命运控制机制的潜力，以提供新的治疗方法。收益将通过关键的临床开发研究支持inobrodib的进展，包括继续参与该公司最近在英国和美国启动的2期DOMMINO-1研究，并于2026年下半年启动全球3期DOMMINO-2试验。筹集的资金还将用于将inobrodib扩展到其他组合和维持治疗环境。 CellCentric首席执行官Will West博士表示：“我们很高兴得到顶级投资者的支持，他们相信inobrodib有潜力解决多发性骨髓瘤的关键需求，特别是在双特异性T细胞接合剂或抗BCMA疗法之后。这是一个重要且不断增长的未满足需求。Inobrodib是一种新的口服给药方式，也是患者的一种潜在的新选择。与泊马度胺和地塞米松联合作为InoPd，我们在经过大量预处理的复发或难治性多发性骨髓瘤患者中表现出了深度反应。在这笔资金的推动下，我们完全有能力完成全口服三联疗法的注册研究，并推进我们在提供变革性治疗方面的进展。” 2025年12月在ASH分享的2期剂量优化数据表明，与经过大量预处理的复发性或难治性多发性骨髓瘤（RRMM）患者的历史替代疗法相比，20mg Inobrodib联合标准剂量的泊马度胺和地塞米松（InoPd）的反应率至少提高了两倍（先前治疗的中位数为五线）。 West表示，由于有足够的现金维持到2029年，明年有可能进行首次公开募股，但该公司也在就并购进行平行对话。 Venrock合伙人Ken Greenberg医学博士表示：“inobrodib的突出之处在于，在经过大量预处理的人群中，临床有效性的一致性以及可管理的安全性。一种具有新型添加方法的口服药物可以在后期治疗中发挥重要作用，也可以在多发性骨髓瘤的整个治疗领域发挥重要作用。我们很高兴能够支持其进入关键研究。” 关注下方公众号，带你看世界!

临床2期

2026-05-06

·FierceBiotech

CellCentric raises $220M series D to advance myeloma drug through registration, eyes potential IPO

CellCentric CEO Will West said the funds will allow the company to “carry out a full registration program without looking over our shoulders.\"\n In the last three years, CellCentric CEO Will West has been on a journey that has transformed how he thinks about the future of his company. He used to be “obsessed with pharma deals,” he told Fierce Biotech. Now, the clinical-stage biotech has enough runway to stay independent and take its drug to market.CellCentric has raised an oversubscribed $220 million series D financing to advance inobrodib, its first-in-class oral small-molecule inhibitor targeting p300/CBP for the treatment of relapsed or refractory multiple myeloma (RRMM) and other cancers, according to a May 6 release.The raise was led by Venrock Healthcare Capital Partners, with participation from Fidelity Management & Research Company, Sofinnova Partners and HBM Healthcare, along with existing investors RA Capital Management, Forbion, Pfizer, Avego Bioscience Capital and American Cancer Society BrightEdge.The funding syndicate, West said, is strong enough to support an IPO if the company decides that is the best next step. “We had a lot of term sheets that we turned down from smaller funds,” West said. “We were in a privileged position.”West said the funds will allow the company to “carry out a full registration program without looking over our shoulders.” That includes supporting two registration-enabling trials and continued development of the p300/CBP inhibitor.Cambridge, England-based CellCentric is currently enrolling U.K. and U.S. patients in a phase 2 trial studying inobrodib in combination with pomalidomide and dexamethasone (InoPd) in multiple myeloma patients. The round will support this trial, an upcoming global phase 3 trial in the second half of this year and tests in additional combinations and treatment settings. Phase 2 data shared in December at the American Society of Hematology demonstrated that 20-mg inobrodib in combination with pomalidomide and dexamethasone resulted in at least a two-fold increase in response rates compared to alternative therapies for patients with heavily pretreated RRMM. West said that 70% of myeloma patients are treated in a community-based setting rather than large academic centers. The oral drug is designed to be taken at home without intensive monitoring. “The fact that we\'re all well-tolerated means there\'s a clear commercial landing point for this,” he said.Multiple myeloma candidates received a boost from the FDA earlier this year when the agency issued draft guidance for the potential use of minimal residual disease and complete response as acceptable endpoints to accelerate the approval of myeloma drugs.CellCentric’s inobrodib isn’t alone in its quest to offer options to patients with RRMM. Bristol Myers Squibb scored two phase 3 wins via drugs developed with its Cereblon E3 ligase modulator program.With enough cash to last through 2029, West said an IPO is a possibility next year, but the company is also having parallel conversations about M&A. What’s different after the latest fundraise and recent data is that CellCentric can choose its own destiny. “We don\'t have to get forced into a corner or do anything that we don\'t want to do,” West said. “Our investors have a strong belief in the product and can support the company long term.”